1155 - 1315 GMT+9
Sunday 29 August
Lunch Symposium 1
Striving for remission with JAK inhibitors in the management of rheumatoid arthritis
Prof. Takeuchi will chair a discussion with Prof Kameda and A/Prof Ӧstӧr on the management of rheumatoid arthritis (RA) with JAK inhibitors and the importance of aiming for remission. Topics to be covered in this symposium include:
- The importance and value of achieving remission in RA
- The role of JAK inhibitors in the management of RA
- The latest efficacy and safety data for Upadacitinib in RA from the SELECT clinical trial program
Chair: Prof Tsutomu Takeuchi, Keio University, Japan

Remission in RA: Latest Evidence of Upadacitinib in Japanese Patients
Prof Hideto Kameda
Toho University, Japan

From Evidence to Experience: Practical Management of Rheumatoid Arthritis with JAK Inhibitors
A/Prof Andrew Östör
Monash University & Cabrini Medical Centre, Melbourne Rheumatology Group, Australia
1735 - 1835 GMT+9
Monday 30 August
Evening Symposium 5
Transforming management in PsA: integrating novel approaches in clinical practice
Prof Atsumi will chair a discussion with Prof Isaacs and Dr Ikeda on the future of Psoriatic arthritis and the role that JAK inhibitors have in its management. Topics to be covered in this symposium include:
- Key manifestations of PsA
- The role of cytokines and JAK signaling in PsA pathogenesis
- Current and future treatment paradigm in PsA
- Overview of the latest efficacy and safety data for Upadacitinib in PsA from the SELECT-PsA Clinical Trial Program.
Chair: Prof Tatsuya Atsumi, Hokkaido University, Japan

The import role of JAKs in the Treatment of Psoriatic Arthritis
Prof John Isaacs
Institute of Cellular Medicine Newcastle University, United Kingdom

The management of Psoriatic Arthritis treatment
A/Prof Kei Ikeda
Chiba University, Japan